is...(vegasvic1)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Anyone who sells before the data next week is WEAK.....
Mr. R so sell & leave cya
US GOV’T., AMBS & BANYAN BIOMARKERS.. Dr. Zimmerman from Bayer on AMBS: "I have been involved with Amarantus formally and informally for the past three years supporting the founders as they work tirelessly to advance MANF to a stage where it has real commercial potential," said Robert J. Zimmerman, SD. "While that effort has been centered on Parkinson's disease, I believe additional opportunities exist to diversify this therapeutic candidate. Ischemia/reperfusion, cardiovascular disease, stroke, traumatic brain injury, diabetes and potentially other disease conditions appear to be impacted by MANF based upon preclinical studies and the literature."
Amarantus BioSciences and Banyan Biomarkers Announce Positive Data from Traumatic Brain Injury Collaboration
PRNewswire/ -- Amarantus BioSciences, Inc. (OTCBB: AMBS), a biotechnology company developing new treatments for brain-related disorders including traumatic brain injury (TBI) based on its proprietary anti-apoptotic therapeutic protein known as MANF and Banyan Biomarkers, the leader in developing in vitro diagnostic products to detect TBI, today announced the successful completion of a collaboration agreement initiated in November 2011 to evaluate MANF's potential as a disease-modifying agent for the treatment of TBI.
"Based on the results produced through this collaboration, we are excited about the potential of the MANF Program in generating new products to treat concussions and other forms of TBI," said Gerald Commissiong , President & CEO of Amarantus. "While this data is early on in development, we will be looking for innovative approaches to accelerate our TBI development program, while using Banyan's proprietary panel of markers as a key metric in our companion drug – diagnostic strategy."
Hillary Clinton's recent concussion TBI (traumatic brain injury along with the NFL (Toi Cook) along with Banyan BIOmarkers research & US Gov't. grants along with AMBS & Banyan working together is no coincidence. If anyone read the 8K from yesterday
Brewer Sports is now involved. I believe that TBI is so big that
the reason for the name change (drop the S) is to split this company & increase shareholder value. AMBS has to many good things going on. I see very shortly a leading Brain surgeon coming on board to help advance research.
To get to a big board this is what will do it instantly.
Dividends to shareholders of record for new TBI Bioscience.
If any follows my posts u will see I am never wrong.
US GOV’T., AMBS & BANYAN BIOMARKERS.. Dr. Zimmerman from Bayer on AMBS: "I have been involved with Amarantus formally and informally for the past three years supporting the founders as they work tirelessly to advance MANF to a stage where it has real commercial potential," said Robert J. Zimmerman, SD. "While that effort has been centered on Parkinson's disease, I believe additional opportunities exist to diversify this therapeutic candidate. Ischemia/reperfusion, cardiovascular disease, stroke, traumatic brain injury, diabetes and potentially other disease conditions appear to be impacted by MANF based upon preclinical studies and the literature."
Mr. M. I agree, if u add up all the parts & pieces of AMBS the market cap could go into the billions with anticiapated royalties.
That is why I feel to fully capitalize on their properties, they will break off pieces into other BIO companies & give shareholders neww stoc as dividends to increase value. This is my opinion but to get up listed this is what will do it near term.
I hope they unlock their true assets. AMBS could be propelled to
#'s nobody has ever mentioned here. We will find out very soon.
Dr. J, when the Govt. gave Banyan 27 mil it wasn't for rent.
I believe that the grant was with a gag order for search results.
Almost every word Banyan uses comes from AMBS. If Banyan does the research for AMBS for TBI we have a UNANIMOUS WINNER.
If u notice Dr. J AMBS rarely if at all mention Banyan yet they have had positive results in the past for TBI. I believe Banyan got the grant to work on TBI for AMBS. IMO.x NYPD det. I luv to investigate where most people stop.
Vegas has just opened (1 1/2 years ago) athe major Brain Institute in the world. Guess where the good Dr & son r from?
Put the pieces of a large puzzle together..
I expect a major PR in the imminent future about adding a Brain Surgeon to the Board & that will take AMBS to new limits. I will say it again TBI is the major catalyst with this company.
The true test of AMBS was going to court in europe & protecting their patents. That really does tell the true story & the worth of Dr. John & Gerald. Happy new year to Dr.John & Gerald.
Mr. G if u read my last post to MR C AMBS has proven results with Banyan on TBI.
shab, PEOPLE FORGET THAT Dr. John had a son Gerald playing football/ The good Dr. has been working on TBI for 10 years or more. He is the leading scientist in this field.
Banyan BIO if u follow them got a govt. grant 27 mil & ambs is working with them 4 years. It is already a success read more...
Amarantus BioSciences and Banyan Biomarkers Announce Positive Data from Traumatic Brain Injury Collaboration
PRNewswire/ -- Amarantus BioSciences, Inc. (OTCBB: AMBS), a biotechnology company developing new treatments for brain-related disorders including traumatic brain injury (TBI) based on its proprietary anti-apoptotic therapeutic protein known as MANF and Banyan Biomarkers, the leader in developing in vitro diagnostic products to detect TBI, today announced the successful completion of a collaboration agreement initiated in November 2011 to evaluate MANF's potential as a disease-modifying agent for the treatment of TBI.
"Based on the results produced through this collaboration, we are excited about the potential of the MANF Program in generating new products to treat concussions and other forms of TBI," said Gerald Commissiong , President & CEO of Amarantus. "While this data is early on in development, we will be looking for innovative approaches to accelerate our TBI development program, while using Banyan's proprietary panel of markers as a key metric in our companion drug – diagnostic strategy."
In in-vitro cell culture experiments, MANF was reproducibly shown to confer neuroprotective properties in various cell death-related pathways. The data raise the possibility that modulating MANF in patients immediately after suffering a TBI and in patients who have suffered multiple concussions over an extended period, could be a successful therapeutic approach to promote recovery after TBI.
"The data shows that MANF has a significant ability to reduce cell death from a variety of insults that simulate Traumatic Brain Injury as we have modeled in multiple assays in our internal laboratories at Banyan," said Dr. Andreas Jeromin , PhD, Senior Director Research at Banyan, "These data give us confidence to move to the next phase of testing to further validate this approach, as well as look at innovative product development strategies to accelerate bringing a MANF-based treatment to patients for TBI."
MR.C the value of the patents alone with royalties is over 250 mil. that is a low #. ambs so undervalued it is crazy
LOCKED INSIDE AMBS is @ least 4 companies all with unlimited potential. IF they were valued separately u would be looking @
$3-$5 share min. IMO i believe this is where we are headed so each division can grow at its own pace.
DRANO, can't disagree with u but it proves my point that AMBS has many different researches going on all at the same time. TO UNLOCK the value of any company u must break off into smaller pieces. That is how to reward shareholders. To rely on only 1 aspect of a company is fools play The board members r very smart and JA BARKATS is the right law firm to pull it off.
Dr. J...what do u think? Hillary Clinton's recent concussion TBI (traumatic brain injury along with the NFL (Toi Cook) along with Banyan BIOmarkers research & US Gov't. grants along with AMBS & Banyan working together is no coincidence. If anyone read the 8K from yesterday
Brewer Sports is now involved. I believe that TBI is so big that
the reason for the name change (drop the S) is to split this company & increase shareholder value. AMBS has to many good things going on. I see very shortly a leading Brain surgeon coming on board to help advance research.
To get to a big board this is what will do it instantly.
Dividends to shareholders of record for new TBI Bioscience.
If any follows my posts u will see I am never wrong.
Just yesterday in college footbal 9 concussions, NFL Sunday 7..
Car accidents last nite..who knows the BIGGER PICTURE for AMBS is TBI.
Hillary Clinton's recent concussion TBI (traumatic brain injury along with the NFL (Toi Cook) along with Banyan BIOmarkers research & US Gov't. grants along with AMBS & Banyan working together is no coincidence. If anyone read the 8K from yesterday
Brewer Sports is now involved. I believe that TBI is so big that
the reason for the name change (drop the S) is to split this company & increase shareholder value. AMBS has to many good things going on. I see very shortly a leading Brain surgeon coming on board to help advance research.
To get to a big board this is what will do it instantly.
Dividends to shareholders of record for new TBI Bioscience.
If any follows my posts u will see I am never wrong.
US GOV’T., AMBS & BANYAN BIOMARKERS.. Dr. Zimmerman from Bayer on AMBS: "I have been involved with Amarantus formally and informally for the past three years supporting the founders as they work tirelessly to advance MANF to a stage where it has real commercial potential," said Robert J. Zimmerman, SD. "While that effort has been centered on Parkinson's disease, I believe additional opportunities exist to diversify this therapeutic candidate. Ischemia/reperfusion, cardiovascular disease, stroke, traumatic brain injury, diabetes and potentially other disease conditions appear to be impacted by MANF based upon preclinical studies and the literature."
Banyan Biomarkers, Inc. Awarded $26.3 Million Department of Defense Contract for Diagnostic Test for Traumatic Brain Injury
ALACHUA, Fla.--(BUSINESS WIRE)--Banyan Biomarkers, Inc., the leader in developing in vitro diagnostic products to detect traumatic brain injury (TBI), announced today that they have been awarded a $26.3 Million Contract for the development of a diagnostic test for TBI.
This award will help fund critical research for a point of care test to diagnose TBI and has significant potential for both military and civilian applications. Jackson Streeter, M.D. and CEO of Banyan Biomarkers, Inc. stated, "We are pleased to be working with the Department of Defense to develop a blood test for TBI. Properly diagnosing TBI will help medical professionals triage and treat our soldiers more effectively."
Each year in the United States, approximately 1.4 million people are treated in emergency rooms because of TBI. Automobile accidents, falls, sports related injuries, and assaults are common causes of TBI. It is estimated that as many as 20% of combat veterans have suffered some degree of traumatic brain injury due to bomb blasts while in Iraq or Afghanistan.
Amarantus BioSciences and Banyan Biomarkers Announce Positive Data from Traumatic Brain Injury Collaboration
PRNewswire/ -- Amarantus BioSciences, Inc. (OTCBB: AMBS), a biotechnology company developing new treatments for brain-related disorders including traumatic brain injury (TBI) based on its proprietary anti-apoptotic therapeutic protein known as MANF and Banyan Biomarkers, the leader in developing in vitro diagnostic products to detect TBI, today announced the successful completion of a collaboration agreement initiated in November 2011 to evaluate MANF's potential as a disease-modifying agent for the treatment of TBI.
"Based on the results produced through this collaboration, we are excited about the potential of the MANF Program in generating new products to treat concussions and other forms of TBI," said Gerald Commissiong , President & CEO of Amarantus. "While this data is early on in development, we will be looking for innovative approaches to accelerate our TBI development program, while using Banyan's proprietary panel of markers as a key metric in our companion drug – diagnostic strategy."
In in-vitro cell culture experiments, MANF was reproducibly shown to confer neuroprotective properties in various cell death-related pathways. The data raise the possibility that modulating MANF in patients immediately after suffering a TBI and in patients who have suffered multiple concussions over an extended period, could be a successful therapeutic approach to promote recovery after TBI.
"The data shows that MANF has a significant ability to reduce cell death from a variety of insults that simulate Traumatic Brain Injury as we have modeled in multiple assays in our internal laboratories at Banyan," said Dr. Andreas Jeromin , PhD, Senior Director Research at Banyan, "These data give us confidence to move to the next phase of testing to further validate this approach, as well as look at innovative product development strategies to accelerate bringing a MANF-based treatment to patients for TBI."
Ditto Don.. time to buy more so u can quit...good year coming for AMBS..GOOD LUK
I can see that AMBS could split into smaller sub corps to really increase shareholder value. They have so much going on.. The patent suit they just won in Europe was the clincher for me.
Who would fight over something of no use or value...
Most of us here are in @ .005 give or take a little. I haven't sold 1 share & not going to. Between me & friends & dr's I know we have over 9 mil & no one is selling. I would risk losing it all before I sell 1 share. I luv the TBI story.. It is huge.
Just today in college 9 concussions for players..NFL...how about Hillary Clinton's concussion.
Projected market cap for Jan. 10th is 150 mil which would put AMBS PPS @.67cents minimum. Just the patents for MANF should cover that.
duelittle..ur right most if not all institutions can't buy penny stocks..that is why we will uplist to let them in..HA HA HA..
BARBERSHOP.I have been following AMBS for years along with the patents they hae purchased from other companies. To much work & money have gone into the research & too many accredited Doctors
are on board. Before TBI I thought we could see .60-.75 cents.
Because of TBI...Banyan...Govt. NFL..head trauma. I see $1.25
by March if not sooner. My next prediction AMBS gets a LEADING
BRAIN SURGEON on board.
barbershop..LIKE I SAID EARLIER TODAY TBI is the bigger picture in the 8K states brewer deals with gov't.s whoa
8k from today.. READ like i said earlier TBI is the big picture.
This Letter of Intent (“LOI”) is made as of this 30th day of December 2012 by and between Amarantus BioScience, Inc. (OTCQB: AMBS) (hereinafter, “AMBS”), Toi Cook Management Group, LLC (“TCMG”)and Brewer Sports International, LLC (“Brewer”). Each of AMBS, TCMG and Brewer may also be referred to herein each as a “Party,” and collectively as the “Parties.”
Brewer is a multi-faceted sports advisory firm within ‘The Brewer Group Companies.’ Brewer focuses on the businesses of sports, wellness and media. Brewer provides services that include sports lending, corporate advisory consulting and identifying media opportunities for professional athletes, sports agencies, sports leagues and player associations. Where appropriate, Brewer may also engage with international organizations and governments, with whom BSI maintains relationships, and support and endorse certain philanthropic causes. Brewer is committed to contributing to advances in the diagnosis and treatment of sport-related concussions, and has prior hereto co-founded with AMBS the ‘Coalition for Concussion Treatment’ (“#C4CT”), an awareness movement seeking to inform the public of the need to develop effective diagnostic tools and treatments for human brain injuries and cognitive disorders.
AMBS is a development-stage biotechnology company founded in January 2008. AMBS develops therapeutic proteins to diagnose and/or treat human medical conditions such as Parkinson’s disease and Traumatic Brain Injury. The proprietary therapeutic protein developed by AMBS chief scientist John W. Commissiong, PhD, is known as Mesencephalic-Astrocyte-derived Neurotrophic Factor (“MANF”). AMBS is currently developing MANF-based products as possible treatments for human brain injuries and disorders. As a Founding Member of the #C4CT along with Brewer, AMBS desires to continue to find outlets to promote the cause of fighting human brain injuries and disorders.
TCMG is a consulting firm specializing in the creation of alliances between businesses and professional sports leagues, professional athletes and/or professional entertainers with the purpose of advancing business opportunities and creating awareness for such opportunities.
This LOI therefore reflects the culmination of prior discussions and information exchanged to date between the Parties regarding their contemplated collaboration to coordinate and co-host a #C4CT Concussion Awareness Conference (the “Conference,” and the Parties’ collaboration relating to the Conference being referred to as the “Transaction”) along with certain other affiliates or associates, which include nationally recognized current and former players in the National Football League (“NFL”).
BARBER when u read anything @ BANYAN BIOMARKERS..it reads as if
AMBS wrote it..use all the same words..I believe that AMBS is very involved @ Banyan & they have a GAG order where they can't disclose anything..but Banyan is very close & Greald stated they have been working closely with Banyan.
With all the head injuries in society TBI is definitely the BIGGER PICTURE.
barber shop..US GOV’T., AMBS & BANYAN BIOMARKERS.. Dr. Zimmerman from Bayer on AMBS: "I have been involved with Amarantus formally and informally for the past three years supporting the founders as they work tirelessly to advance MANF to a stage where it has real commercial potential," said Robert J. Zimmerman, SD. "While that effort has been centered on Parkinson's disease, I believe additional opportunities exist to diversify this therapeutic candidate. Ischemia/reperfusion, cardiovascular disease, stroke, traumatic brain injury, diabetes and potentially other disease conditions appear to be impacted by MANF based upon preclinical studies and the literature."
TBI IMO is the real deal for AMBS.
bareber shop..Banyan Biomarkers, Inc. Awarded $26.3 Million Department of Defense Contract for Diagnostic Test for Traumatic Brain Injury
ALACHUA, Fla.--(BUSINESS WIRE)--Banyan Biomarkers, Inc., the leader in developing in vitro diagnostic products to detect traumatic brain injury (TBI), announced today that they have been awarded a $26.3 Million Contract for the development of a diagnostic test for TBI.
This award will help fund critical research for a point of care test to diagnose TBI and has significant potential for both military and civilian applications. Jackson Streeter, M.D. and CEO of Banyan Biomarkers, Inc. stated, "We are pleased to be working with the Department of Defense to develop a blood test for TBI. Properly diagnosing TBI will help medical professionals triage and treat our soldiers more effectively."
Each year in the United States, approximately 1.4 million people are treated in emergency rooms because of TBI. Automobile accidents, falls, sports related injuries, and assaults are common causes of TBI. It is estimated that as many as 20% of combat veterans have suffered some degree of traumatic brain injury due to bomb blasts while in Iraq or Afghanistan.
barbershop ur right the big picture is TBI (Traumatic Brain Injury)..
Amarantus BioSciences and Banyan Biomarkers Announce Positive Data from Traumatic Brain Injury Collaboration
PRNewswire/ -- Amarantus BioSciences, Inc. (OTCBB: AMBS), a biotechnology company developing new treatments for brain-related disorders including traumatic brain injury (TBI) based on its proprietary anti-apoptotic therapeutic protein known as MANF and Banyan Biomarkers, the leader in developing in vitro diagnostic products to detect TBI, today announced the successful completion of a collaboration agreement initiated in November 2011 to evaluate MANF's potential as a disease-modifying agent for the treatment of TBI.
"Based on the results produced through this collaboration, we are excited about the potential of the MANF Program in generating new products to treat concussions and other forms of TBI," said Gerald Commissiong , President & CEO of Amarantus. "While this data is early on in development, we will be looking for innovative approaches to accelerate our TBI development program, while using Banyan's proprietary panel of markers as a key metric in our companion drug – diagnostic strategy."
In in-vitro cell culture experiments, MANF was reproducibly shown to confer neuroprotective properties in various cell death-related pathways. The data raise the possibility that modulating MANF in patients immediately after suffering a TBI and in patients who have suffered multiple concussions over an extended period, could be a successful therapeutic approach to promote recovery after TBI.
"The data shows that MANF has a significant ability to reduce cell death from a variety of insults that simulate Traumatic Brain Injury as we have modeled in multiple assays in our internal laboratories at Banyan," said Dr. Andreas Jeromin , PhD, Senior Director Research at Banyan, "These data give us confidence to move to the next phase of testing to further validate this approach, as well as look at innovative product development strategies to accelerate bringing a MANF-based treatment to patients for TBI."
4 ACES ur right I'll see ur 4aces & raise with my royal flush AMBS HO HO HO. Thank u shorties..c u @ the top... ha ha ha.
don't worry..we hae reports & PR after new years..break out the champagne
The delay is they have additional data for TBI & it will give additional shareholder value..IMO Gerald in the latest 8K referred
to that in a vague way IMO.
The bigger picture for AMBS is TBI (traumatic brain injury..Read
We have the US Govt. funding, AMBS & Banyan Biomarkers in a JV &
they r the only companies very close to a breakthru. Dr. Z states
"I believe additional opportunities.....
Dr.Zimmerman from Bayer on AMBS: "I have been involved with Amarantus formally and informally for the past three years supporting the founders as they work tirelessly to advance MANF to a stage where it has real commercial potential," said Robert J. Zimmerman, SD. "While that effort has been centered on Parkinson's disease, I believe additional opportunities exist to diversify this therapeutic candidate. Ischemia/reperfusion, cardiovascular disease, stroke, traumatic brain injury, diabetes and potentially other disease conditions appear to be impacted by MANF based upon preclinical studies and the literature."
Banyan Biomarkers, Inc. Awarded $26.3 Million Department of Defense Contract for Diagnostic Test for Traumatic Brain Injury
ALACHUA, Fla.--(BUSINESS WIRE)--Banyan Biomarkers, Inc., the leader in developing in vitro diagnostic products to detect traumatic brain injury (TBI), announced today that they have been awarded a $26.3 Million Contract for the development of a diagnostic test for TBI.
This award will help fund critical research for a point of care test to diagnose TBI and has significant potential for both military and civilian applications. Jackson Streeter, M.D. and CEO of Banyan Biomarkers, Inc. stated, "We are pleased to be working with the Department of Defense to develop a blood test for TBI. Properly diagnosing TBI will help medical professionals triage and treat our soldiers more effectively."
Each year in the United States, approximately 1.4 million people are treated in emergency rooms because of TBI. Automobile accidents, falls, sports related injuries, and assaults are common causes of TBI. It is estimated that as many as 20% of combat veterans have suffered some degree of traumatic brain injury due to bomb blasts while in Iraq or Afghanistan.
Amarantus BioSciences and Banyan Biomarkers Announce Positive Data from Traumatic Brain Injury Collaboration
SUNNYVALE, Calif. and ALACHUA, Fla., June 7, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCBB: AMBS), a biotechnology company developing new treatments for brain-related disorders including traumatic brain injury (TBI) based on its proprietary anti-apoptotic therapeutic protein known as MANF and Banyan Biomarkers, the leader in developing in vitro diagnostic products to detect TBI, today announced the successful completion of a collaboration agreement initiated in November 2011 to evaluate MANF's potential as a disease-modifying agent for the treatment of TBI.
"Based on the results produced through this collaboration, we are excited about the potential of the MANF Program in generating new products to treat concussions and other forms of TBI," said Gerald Commissiong , President & CEO of Amarantus. "While this data is early on in development, we will be looking for innovative approaches to accelerate our TBI development program, while using Banyan's proprietary panel of markers as a key metric in our companion drug – diagnostic strategy."
In in-vitro cell culture experiments, MANF was reproducibly shown to confer neuroprotective properties in various cell death-related pathways. The data raise the possibility that modulating MANF in patients immediately after suffering a TBI and in patients who have suffered multiple concussions over an extended period, could be a successful therapeutic approach to promote recovery after TBI.
"The data shows that MANF has a significant ability to reduce cell death from a variety of insults that simulate Traumatic Brain Injury as we have modeled in multiple assays in our internal laboratories at Banyan," said Dr. Andreas Jeromin , PhD, Senior Director Research at Banyan, "These data give us confidence to move to the next phase of testing to further validate this approach, as well as look at innovative product development strategies to accelerate bringing a MANF-based treatment to patients for TBI."